

## YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease

Advances in acute cardiovascular care have rebutted the old paradigm that diabetics without previous myocardial infarction have the same cardiovascular risk as non-diabetics with myocardial infarction (1). The prognosis of diabetes patients is better determined by long-term medical management than acute interventions (2). The cardiovascular event and death risk of diabetics remains twice as that of non-diabetics (3).

Thus, the investigation of new and additional pathways that account for the increased atherosclerosis burden, which in turn causes cardiovascular events, is mandatory.

In this issue of *The Anatolian Journal of Cardiology*, Akboğa et al. (4) entitled "Increased serum YKL-40 level is associated with the presence and severity of metabolic syndrome." showed that YKL-40 is associated with metabolic syndrome as defined by NCEP-ATP III criteria. Levels of YKL-40 correspond with the numbers of individual components of the metabolic syndrome (4). Furthermore, ROC analysis revealed a comparable power of YKL-40 [AUC: 0.785 (0.718–0.853),  $p < 0.001$ ] to hs-CRP [0.804 (0.735–0.872),  $p < 0.001$ ] (4).

Till date, the association of YKL-40 with obesity, metabolic syndrome, morbid obesity, and cardiovascular disease is complex.

YKL-40, produced by the gene chitinase 3-like 1 (CH3L1) (5, 6), is a heparin- and chitin-binding lectin without chitinase activity and a member of the mammalian chitinase-like protein cluster (6). YKL-40 belongs to the glycosyl hydrolase family 18, which consists of enzymes and proteins, and includes hydrolytic enzymes from various species, including mammalian, bacteria, fungi, nematodes, insects, and plants (6). YKL-40 is secreted by activated macrophages, activated neutrophils, arthritic chondrocytes, fibroblast-like synovial cells, osteoblasts, and differentiated vascular smooth muscle cells (5).

Minor researches have been conducted on the exact functions of YKL-40 so far. Several studies have suggested that YKL-40 is an essential factor in extracellular tissue remodeling. It controls mitogenesis via MAP kinase and PI-3K signaling cascades in fibroblasts (7, 8). Those initial observations led to a first identification of the involvement of YKL-40 in cancer (7) and rheumatoid disorders (9).

YKL-40's association with migration, reorganization, and adhesion of endothelial cells and smooth muscle cells suggests a role in angiogenesis (7, 8).

Indeed, stimulated by an initial review of Rathcke et al. (10), numerous investigators have studied the influence of YKL-40 on cardiovascular disease. Recently, a Mendelian analysis in 96 110 individuals from the Danish general population revealed that elevated YKL-40 is associated with a 34% increase in triglycerides and a two-fold increased risk of ischemic stroke (11). Noteworthy, genetically elevated YKL-40 was not a cause of stroke (11).

Thus, risk factor-related increase of YKL-40 might be a simple measure of risk increase but may also be independently involved in associated pathways. Thus, the findings that YKL-40 is linked to metabolic syndrome (4), morbid obesity (12), type 2 diabetes mellitus (13), type 1 diabetes mellitus (14), and albuminuria (13, 15) suggests an interaction in the development and progression of atherosclerosis in patients with those comorbidities.

Because YKL-40 synergistically acts with IGF-1 and initiates MAPK and PI3K signaling in fibroblasts, it might be of interest to investigate those pathways (7, 8) in cells, such as endothelial cells or smooth muscle cells.

**Gerit-Holger Schernthaner, Clemens Höbaus, Johanna Brix<sup>1</sup>**  
**Department of Medicine II, Medical University of Vienna; Vienna-Austria**  
<sup>1</sup>**Department of Medicine I, Rudolfstiftung Hospital; Vienna-Austria**

### References

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998; 339: 229-34.
2. Cubbon RM, Wheatcroft SB, Grant PJ, Gale CP, Barth JH, Sapsford RJ, et al Evaluation of Methods and Management of Acute Coronary Events Investigators. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. *Eur Heart J* 2007; 28: 540-5.
3. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* 2010; 375: 2215-22.
4. Akboğa MK, Yalçın R, Şahinaslan A, Demirtaş CY, Paşaoğlu H, Abacı A. et al. Increased serum YKL-40 level is associated with the presence and severity of metabolic syndrome. *Anatolian J Cardiol* 2016; 16: 953-8.

**Address for correspondence:** Gerit-Holger Schernthaner, MD, Medical University of Vienna  
 Department of Medicine II, Waehringer Guertel 18-20  
 A-1090 Vienna-Austria

Phone: 0043.1.40400.46710 Fax: 0043.1.40400.46650 E-mail: gerit.schernthaner@meduniwien.ac.at

**Accepted Date:** 05.05.2016

©Copyright 2016 by Turkish Society of Cardiology - Available online at [www.anatoljcardiol.com](http://www.anatoljcardiol.com)  
 DOI:10.14744/AnatolJCardiol.2016.22332



5. Millis AJ, Hoyle M, Reich E, Mann DM. Isolation and characterization of a Mr=38,000 protein from differentiating smooth muscle cells. *J Biol Chem* 1985; 260: 3754-61.
6. Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L, Andreesen R, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. *J Biol Chem* 2003; 278: 44058-67.
7. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? *Cancer Epidemiol Biomarkers Prev* 2006; 15: 194-202.
8. Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. *Exp Cell Res* 2003; 287: 79-87.
9. Vos K, Steenbakkens P, Miltenburg AM, Bos E, van Den Heuvel MW, van Hogezaand RA, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. *Ann Rheum Dis* 2000; 59: 544-8.
10. Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. *Inflamm Res* 2006; 55: 221-7.
11. Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Elevated plasma YKL-40, lipids and lipoproteins, and ischemic vascular disease in the general population. *Stroke* 2015; 46: 329-35.
12. Hempen M, Kopp HP, Elhenicky M, Höbaus C, Brix JM, Koppensteiner R, et al. YKL-40 is elevated in morbidly obese patients and declines after weight loss. *Obes Surg* 2009; 19: 1557-63.
13. Brix JM, Höllerl F, Koppensteiner R, Schernthaner G, Schernthaner GH. YKL-40 in type 2 diabetic patients with different levels of albuminuria. *Eur J Clin Invest* 2011; 41: 589-96.
14. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. *Diabetes Care* 2009; 32: 323-8.
15. Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. *Inflamm Res* 2006; 55: 53-9.



From Prof. Dr. Arif Aksit's collection